Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCohort Regulatory News (CHRT)

Share Price Information for Cohort (CHRT)

Share Price is delayed by 15 minutes
Get Live Data
1,298.00    42.00 (3.34%)
Bid:
1,210.00
Ask:
1,298.00
Spread: 88.00 (7.273%)
Market Cap: £575.57m
CHRT Live PriceLast checked at - London Stock Exchange

Intraday Cohort Share Chart

Full Year Trading Update

23 May 2024 07:00

RNS Number : 5474P
Cohort PLC
23 May 2024
 

One Waterside Drive

Arlington Business Park

Reading

Berks

RG7 4SW

 

 

23 May 2024

 

 

COHORT PLC

("Cohort" or "the Group")

 

Full Year Trading Update

 

Performance slightly ahead of expectations

Record closing order book

 

Cohort, the independent technology Group, today provides an unaudited trading update for its financial year ended 30 April 2024.

 

Summary

 

· Trading performance for the year ended 30 April 2024 is slightly ahead of expectations, with growth in revenue and profits compared to the year ended 30 April 2023.

· Strong net funds of c.£23m, ahead of expectations (30 April 2023: £15.6m; 31 October 2023: £13.3m).

· Very strong order intake of c.£387m (2023: £218m)

· Record closing order book of c.£518m (30 April 2023: £329.1m) including the £135m Royal Navy countermeasures contract awarded to SEA in March 2024

· Order book underpins c.£180m (90%) of current market revenue expectations for the year ended 30 April 2025 (2024: £145m, 84%).

 

 

FY24 year-end update

 

Following a strong second half profit performance, Cohort has delivered results slightly ahead of expectations for the year. The Group has seen robust growth within the Sensors and Effectors division, offset by somewhat weaker trading seen within the Communications and Intelligence division.

 

Sensors and Effectors saw robust growth across all its constituent businesses but particularly within Chess and SEA. Chess continued its growth trajectory following its turnaround performance last year, with SEA continuing to secure and deliver on large naval orders.

 

In Communications and Intelligence, as expected, UK MOD product orders decreased from the high levels seen in 2022/23, whilst we continued to see contract delays within Portugal.

 

The closing net funds position was ahead of expectations and arose from favourable timing of working capital flows and delayed capital expenditure due to adverse winter weather, on our new facility in Germany, which will now take place in the 2024/25 financial year.

 

The order intake is c.1.9x the annual revenue (2023: 1.2x). Following significant contract awards during the year, the order book exceeded half a billion pounds for the first time, with on-order revenue now extending to 2037. The order intake performance was c.80% higher than last year.

 

The year end order book underpins c.£180m (90%) of the current consensus market revenue expectations for 2024/25, an improvement on the year just finished.

 

Outlook for FY25

 

Cohort continues to see good demand for our products and services from both our domestic customers, especially the UK, and from export customers. The drivers for increased investment in defence have amplified during the year, with the ongoing conflicts in Ukraine and the Middle East, coupled with tensions in the Indo-Pacific region leading to increased global defence spending.

 

The Royal Navy's recent order for the Ancilia Trainable Decoy Launcher System, was a significant milestone for the Group. It represents a strong vote of confidence in the product; a fully UK designed and built solution for which we see encouraging export prospects. As stated in our announcement of 26 March 2024, this together with other recent order wins, is expected to materially enhance the Group's earnings.

 

We have an encouraging pipeline of order opportunities for the current year, providing a positive outlook for organic growth in the years ahead. Overall, our expectations for the coming financial year remain unchanged.

 

Notice of FY24 results

 

It is the Group's intention to issue its preliminary announcement for the year ended 30 April 2024 in late July 2024.

 

Andrew Thomis, Chief Executive of Cohort, said:

 

"Cohort's performance was slightly ahead of our previous expectations for the year with growth in revenue and profits. Following strong order intake, we have a record closing order book with encouraging prospects for further orders. Our strong closing net funds position provides a robust platform from which to invest in the business and, potentially, acquisitions. We expect to continue our organic growth in 2024/25 and beyond."

 

 

ENDS

 

 

For further information please contact:

 

Cohort plc

0118 909 0390

Andrew Thomis, Chief Executive

Simon Walther, Finance Director

Raquel McGrath, Company Secretary

Emily McBride, Group Head of Marketing & Corporate Communications

Investec Bank Plc (NOMAD and Broker)

020 7597 5970

Carlton Nelson, Christopher Baird

MHP

07817 458 804

Reg Hoare, Ollie Hoare, Hugo Harris

cohort@mhpgroup.com

 

 

NOTES TO EDITORS

 

Cohort plc (www.cohortplc.com) is the parent company of six innovative, agile and responsive businesses based in the UK, Germany and Portugal, providing a wide range of services and products for domestic and export customers in defence and related markets.

 

Cohort (AIM: CHRT) was admitted to London's Alternative Investment Market in March 2006. It has headquarters in Reading, Berkshire and employs in total over 1,250 core staff there and at its other operating company sites across the UK, Germany, and Portugal.

 

The group is split into two segments - Communications and Intelligence, and Sensors and Effectors:

 

Communications and Intelligence

· EID designs and manufactures advanced communications systems for naval and military customers. Cohort acquired a majority stake in June 2016. www.eid.pt

 

· MASS is a specialist data technology company serving the defence and security markets, focused on electronic warfare, digital services, and training support. Acquired by Cohort in August 2006. www.mass.co.uk

 

· MCL designs, sources, and supports advanced electronic and surveillance technology for UK end users including the MOD and other government agencies. MCL has been part of the Group since July 2014. www.marlboroughcomms.com

 

Sensors and Effectors

· Chess Dynamics offers surveillance, tracking and fire-control systems to the defence and security markets. Chess has been part of the Group since December 2018. www.chess-dynamics.com

 

· ELAC SONAR supplies advanced sonar systems and underwater communications to global customers in the naval marketplace. Acquired by Cohort in December 2020. www.elac-sonar.de 

 

· SEA delivers and supports technology-based products for the defence and transport markets alongside specialist research and training services. Acquired by Cohort in October 2007. www.sea.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFITEVIFFIS
Date   Source Headline
1st Jun 202611:41 amRNSTotal Voting Rights
27th May 20267:00 amRNSFull Year Trading Update
26th May 20267:00 amRNSNotice of Full Year Trading Update
12th May 202610:46 amRNSHolding(s) in Company
1st May 20269:37 amRNSTotal Voting Rights
10th Apr 20263:58 pmRNSDirector/PDMR Shareholding
10th Apr 202612:35 pmRNSHolding(s) in Company
2nd Apr 20267:00 amRNSBlock Listing Six Monthly Return
1st Apr 202610:10 amRNSTotal Voting Rights
26th Mar 20267:00 amRNSContract Announcement
23rd Mar 20267:00 amRNSContract Announcement
2nd Mar 202611:57 amRNSTotal Voting Rights
25th Feb 20269:51 amRNSBlock Listing Six Monthly Return
20th Feb 20267:00 amRNSDirector/PDMR Shareholding
17th Feb 20263:41 pmRNSHolding(s) in Company
16th Feb 20267:00 amRNSDirector/PDMR Shareholding
4th Feb 20269:35 amRNSHolding(s) in Company
2nd Feb 20264:54 pmRNSTotal Voting Rights
30th Jan 20267:00 amRNSContract Wins
20th Jan 202612:40 pmRNSHolding(s) in Company
15th Jan 20267:00 amRNSInterim Report 2025
5th Jan 20269:00 amRNS-RInvestor Presentation via Equity Development
2nd Jan 202612:40 pmRNSTotal Voting Rights
22nd Dec 20259:00 amRNS-RInvestor Presentation via Engage Investor
22nd Dec 20259:00 amRNS-RInvestor Presentation via Engage Investor
15th Dec 202511:56 amRNSDirector/PDMR Shareholding
11th Dec 20257:00 amRNSDirector/PDMR Shareholding
10th Dec 20257:01 amRNSHalf Year Results
1st Dec 202512:20 pmRNSTotal Voting Rights
28th Nov 20257:00 amRNSNotice of Half Year Results
4th Nov 202511:59 amRNSTotal Voting Rights
27th Oct 20254:37 pmRNSDirector/PDMR Shareholding
16th Oct 202510:11 amRNSDirector/PDMR Shareholding
7th Oct 20253:15 pmRNSDirector/PDMR Shareholding
7th Oct 20257:00 amRNSMASS secures £15.7m countermeasures contract
2nd Oct 202511:03 amRNSBlock Listing Six Monthly Return
1st Oct 20259:53 amRNSTotal Voting Rights
25th Sep 20254:59 pmRNSResult of AGM
25th Sep 20257:00 amRNSAGM Statement
19th Sep 20255:12 pmRNSDirector/PDMR Shareholding
12th Sep 20257:00 amRNS-RInvestor Presentation
10th Sep 20253:21 pmRNSDirector/PDMR Shareholding
3rd Sep 202510:57 amRNSDirector/PDMR Shareholding
1st Sep 202511:05 amRNSTotal Voting Rights
26th Aug 20253:22 pmRNSBlock Listing Six Monthly Return
20th Aug 20253:56 pmRNSAnnual Report and Notice of Annual General Meeting
15th Aug 20253:35 pmRNSDirector/PDMR Shareholding
11th Aug 20255:10 pmRNSDirector/PDMR Shareholding
1st Aug 20254:16 pmRNSTotal Voting Rights
17th Jul 20259:49 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.